Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Mortality rates in matched cohort, pseudo-randomised and randomised trials of convalescent plasma given to COVID-19 patients

Amar Ahmad, Marwa Salsabil, View ORCID ProfileTim Oliver
doi: https://doi.org/10.1101/2020.11.19.20234757
Amar Ahmad
1Research Scientist New York University, AD, email
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: asa12@nyu.edu
Marwa Salsabil
2Research assistant Barts Cancer Institute,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Marwa.salsabil@student.anglia.ac.uk
Tim Oliver
3Professor Emeritus Barts Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tim Oliver
  • For correspondence: r.t.oliver@qmul.ac.uk r.t.oliver@qmul.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction For more than 80 years convalescent or immune sera has been used in severe life threatening infections. Since March of this year a rapidly increasing number of publications have reported series of Convalescent plasma (CP) investigations in severely ill COVID-19 patients.

Objective a brief CP scoping review focusing on early mortality

Methods We searched available data bases. Three randomised trials, two pseudo-randomised observations and twelve matched cohort studies were identified. Random-effects meta-analyses were performed on extracted data

Results A total of 2,378 CP treated and 5188 “controls” in 17 studies. Individually only two studies were significant for reduction of deaths to 30 days, but all showed a similar percentage reduction. When pooled, meta-analysis was undertaken. It showed that the overall reduction of death was significant for all series RR 0.710 (p=0.00001), all matched cohort series RR = 0.610 (p-value = 0.001) and the two pseudo-randomised series RR 0.747 (p=0.005) but not the three technically inadequate randomised trials, RR 0.825 (p=0.397). In two of these randomised trials, there was faster clearance of Viral DNA at 72 hours after CP than placebo

Conclusion It is hoped the significance of this less than perfect data will increase interest in completing the delayed randomised trials as the results suggest they could be better than currently licenced drugs. Given increasing published evidence of increased risk of both diagnosis and death from COVID-19 in patients with severe Vitamin-D deficiency, future studies should also study influence of Vitamin-D status of donor and recipient on outcome.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

There was no funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

NA

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

contact asa12@nyu.edu

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 20, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Mortality rates in matched cohort, pseudo-randomised and randomised trials of convalescent plasma given to COVID-19 patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Mortality rates in matched cohort, pseudo-randomised and randomised trials of convalescent plasma given to COVID-19 patients
Amar Ahmad, Marwa Salsabil, Tim Oliver
medRxiv 2020.11.19.20234757; doi: https://doi.org/10.1101/2020.11.19.20234757
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Mortality rates in matched cohort, pseudo-randomised and randomised trials of convalescent plasma given to COVID-19 patients
Amar Ahmad, Marwa Salsabil, Tim Oliver
medRxiv 2020.11.19.20234757; doi: https://doi.org/10.1101/2020.11.19.20234757

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (525)
  • Anesthesia (125)
  • Cardiovascular Medicine (1435)
  • Dentistry and Oral Medicine (220)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10335)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2656)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (682)
  • Hematology (269)
  • HIV/AIDS (571)
  • Infectious Diseases (except HIV/AIDS) (12119)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (276)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2484)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (497)
  • Occupational and Environmental Health (569)
  • Oncology (1335)
  • Ophthalmology (403)
  • Orthopedics (153)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (345)
  • Pediatrics (786)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (297)
  • Psychiatry and Clinical Psychology (2422)
  • Public and Global Health (5032)
  • Radiology and Imaging (902)
  • Rehabilitation Medicine and Physical Therapy (536)
  • Respiratory Medicine (688)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)